Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.79 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.79 |
| ▸ | GRM7 | Q14831 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | AHCY | P23526 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL53322 | 0.89 | MTNR1A (1.00) | MTNR1AMTNR1BGRM7MAPTALDH1A1 | |
| SCHEMBL27731471 | 0.81 | MAPT (0.63) | MTNR1AMTNR1BGRM7MAPTNPC1 | |
| SCHEMBL1628829 | 0.81 | MAPT (0.63) | MTNR1AMTNR1BGRM7MAPTNPC1 | |
| SCHEMBL6359193 | 0.81 | MTNR1A (0.79) | MTNR1AMTNR1BGRM7MAPTHRH3 | |
| Hydrochloric Acid SCHEMBL15483948 | 0.80 | MAPT (0.61) | MTNR1AMTNR1BGRM7MAPTNPC1 | |
| Hydrochloric Acid SCHEMBL11568569 | 0.80 | MAPT (0.61) | MTNR1AMTNR1BGRM7MAPTNPC1 | |
| SCHEMBL10421952 | 0.80 | MAPT (0.71) | MTNR1AMTNR1BGRM7MAPTHRH3 | |
| SCHEMBL1576601 | 0.80 | MTNR1A (0.54) | MTNR1AMTNR1BGRM7MAPTNPC1 | |
| SCHEMBL10804933 | 0.79 | MAPT (0.69) | MTNR1AMTNR1BGRM7MAPTNPC1 | |
| SCHEMBL4858101 | 0.79 | MAPT (0.69) | MTNR1AMTNR1BGRM7MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407960-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1806346-A1 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070004751-A1 | Substituted heterocyclic compounds | ELZEIN ELFATIH | 2007-01-04 | — | — | US | disclosed |
| US-7125876-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040152890-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152890-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | MTNR1A 1715/4885MTNR1B 690/4885GRM7 4123/4885 |
| US-20070004751-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | MTNR1A 1937/4885MTNR1B 778/4885GRM7 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.